Loading
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
Latest quote
$13.81
−$0.02 · -0.14%
Regular session · ET · Market data may be delayed.
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
Regular session · ET · Market data may be delayed.
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
| Metric (USD) | FY2025 |
|---|---|
| Research and development | 153.09M USD |
| Selling, general, and administrative | 48.75M USD |
| Operating expenses | 201.84M USD |
| Interest income | 6.85M USD |
| Depreciation and amortization | 5.85M USD |
| Operating income | −201.84M USD |
| Net income | −191.94M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM10.01M0.01%78.56B USD0.19%$275.77-0.69%
iShares Russell 2000 Growth ETFIWO2.2M0.02%14.25B USD0.24%$351.96-0.96%
Vanguard Morningstar Total Stock Market ETFVTI1.91M0.00%2.3T USD0.03%$379.74-0.34%
Schwab U.S. Small-Cap ETFSCHA1.81M0.01%21.7B USD0.03%$32.42-0.58%
iShares Russell 2000 Value ETFIWN1.4M0.01%13.92B USD0.24%$209.16-0.41%
Vanguard Extended Market ETFVXF670.4K0.00%95.4B USD0.05%$232.04-0.62%
Goldman Sachs Small Cap Equity ETFGSC507.32K0.18%281.34M USD0.80%$62.06-1.30%
Vanguard Russell 2000 ETFVTWO319.66K0.00%18B USD0.06%$111.37-0.75%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Morningstar Total Stock Market ETFVTISchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Value ETFIWNVanguard Extended Market ETFVXFGoldman Sachs Small Cap Equity ETFGSCVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
